# US 2012/0252801 A1 · Antifungal compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252801 A1
- Document ID: US20120252801A1
- Status: Published application
- Kind: A1
- Application number: 13/516,420
- Filed: 2010-12-15
- Published: 2012-10-04
- Earliest claimed: 2009-12-15
- Assignees: Katholieke Universiteit Leuven, K.U.Leuven R&D
- Inventors: Dorothée Bardiot; Bruno Cammue; Patrick Chaltin; Arnaud Marchand; Karin Thevissen
- Web page: https://patentgrep.com/patent/US20120252801A1

## CPC

- C07D 265/32: with oxygen atoms directly attached to ring carbon atoms
- A61P 31/10: Antimycotics
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a series of novel compounds which have been shown to possess antifungal activity. The invention therefore relates to the new compounds, methods for their preparation, pharmaceutical compositions comprising them and to the compounds for use as a medicament, more in particular antifungal medicament.

## Claims

### Claim 1

A compound having a structure according to the formula (A):
wherein,
each R1 and R2 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; and arylheteroalkynyl;
provided that at least one of R1 and R2 is not hydrogen;
each R3 and R4 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl;
R5 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; arylalkyl; arylalkenyl; arylalkynyl; —C(O)R10; and —S(O)2R10;
wherein each of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, and arylalkynyl can be unsubstituted or substituted with one or more substituents each independently selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, ═O, halogen, —SH, ═S, trifluoromethyl, —OCF3, cyano, nitro, —C(O)OH, or —NH2;
each R6 and R7 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl;
each R8 and R9 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; and heterocycle-heteroalkynyl; and wherein R8 and R9 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle;
provided that at least one of R8 and R9 is not hydrogen; and
wherein each of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, and heterocycle-heteroalkynyl, can be unsubstituted or substituted with one or more R11;
each R10 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; arylalkyl; arylalkenyl; and arylalkynyl;
wherein each of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, and arylalkynyl can be unsubstituted or substituted with one or more substituents each independently selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, ═O, halogen, —SH, ═S, trifluoromethyl, —OCF3, cyano, nitro, —C(O)OH, or —NH2;
each R11 is independently selected from the group consisting of halogen; hydroxyl; sulfhydryl; —OZ2; ═O; —SZ2; ═S; —S(O)Z2; —S(O)2Z3; —S(O)2NZ4Z5; trifluoromethyl; nitro; —NZ4Z5; —NZ4S(O)2Z2; —NZ4C(O)Z2; —NZ4C(O)NZ4Z5; cyano; —C(O)Z3; —C(O)NZ4Z5; —C(O)H; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl, heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;
and wherein said alkyl, cyclic alkyl, alkenyl, cyclic alkenyl, alkynyl, cyclic alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from the group of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, ═O, halogen, —SH, ═S, trifluoromethyl, —OCF3, cyano, nitro, —C(O)OH, or —NH2;
each Z2 is independently selected from alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;
wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, ═O, halogen, —SH, ═S, trifluoromethyl, —OCF3, cyano, nitro, —C(O)OH, or —NH2;
each Z3 is independently selected from hydroxyl; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;
wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more selected from the group of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, ═O, halogen, —SH, ═S, trifluoromethyl, —OCF3, cyano, nitro, —C(O)OH, or —NH2;
each Z4 and Z5 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;
wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more selected from the group of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, ═O, halogen, —SH, ═S, trifluoromethyl, —OCF3, cyano, nitro, —C(O)OH, or —NH2;
and wherein Z4 and Z5 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted with alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, ═O, halogen, —SH, ═S, trifluoromethyl, —OCF3, cyano, nitro, —C(O)OH, or —NH2;
and isomers, solvates, pharmaceutically acceptable salts or prodrugs thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein R5 is alkyl.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein R8 is hydrogen.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R3 and R4 are hydrogen.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R1 and R2 are each alkyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the compound has a structure according to formula (Fa) to (Fd):

### Claim 7 (depends on 1)

The compound according to claim 1 selected from the list of
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(1-methyl-1H-indol-5-yl)acetamide;
N-(4-chlorobenzyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(2,3-dihydro-1H-inden-1-yl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(benzo[d]thiazol-5-yl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)acetamide;
N-benzyl-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(pyridin-3-yl)acetamide;
N-(1-benzylpiperidin-4-yl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(1-phenylethyl)acetamide;
3-(2-(4-benzylpiperidin-1-yl)-2-oxoethyl)-4-ethyl-6,6-dimethylmorpholin-2-one;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(pyridin-4-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(quinazolin-2-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-phenethylacetamide;
4-ethyl-6,6-dimethyl-3-(2-oxo-2-(4-phenylpiperazin-1-yl)ethyl)morpholin-2-one;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(pyridin-2-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(thiophen-2-ylmethyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(furan-2-ylmethyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-methyl-N-phenylacetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(pyrimidin-4-yl)acetamide;
N-(3,5-dimethylisoxazol-4-yl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(1-methyl-1H-pyrazol-5-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(3-phenyl-1,2,4-thiadiazol-5-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(1-methyl-1H-pyrazol-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)acetamide;
4-ethyl-6,6-dimethyl-3-(2-oxo-2-(1H-pyrazol-1-yl)ethyl)morpholin-2-one;
N-(4,5-dimethylthiazol-2-yl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N,N-diethyl-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-isobutylacetamide;
N-cyclohexyl-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-propylacetamide;
N-tert-butyl-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(3,3-dimethylbutyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(2,2,2-trifluoroethyl)acetamide;
N-cyclopentyl-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
4-ethyl-6,6-dimethyl-3-(2-oxo-2-(pyrrolidin-1-yl)ethyl)morpholin-2-one;
N-ethyl-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-sec-butyl-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(cyclohexylmethyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N,N-dimethylacetamide;
N-(3-chlorobenzyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(3,4-dichlorobenzyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(2,6-dichlorobenzyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(2-chlorobenzyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
4-ethyl-6,6-dimethyl-3-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)morpholin-2-one;
N-cyclopropyl-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-phenoxyphenyl)acetamide;
N-(4-tert-butylthiazol-2-yl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(2-methylbenzyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(3-methylbenzyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-methylbenzyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(2-(trifluoromethyl)benzyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(3-(trifluoromethyl)benzyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-(trifluoromethyl)benzyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(2-methoxybenzyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(3-methoxybenzyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-methoxybenzyl)acetamide;
N-(biphenyl-2-ylmethyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(biphenyl-3-ylmethyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
N-(biphenyl-4-ylmethyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-2-oxo-6-phenylmorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-((6S)-4-ethyl-2-oxo-6-phenylmorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-((6R)-4-ethyl-2-oxo-6-phenylmorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-((6S)-4-ethyl-6-methyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-((6R)-4-ethyl-6-methyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-ethyl-6-methyl-2-oxo-6-phenylmorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-ethyl-6-methyl-2-oxo-6-phenylmorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-ethyl-5,5,6,6-tetramethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-ethyl-5,6,6-trimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
N-(4-isopropylphenyl)-2-(4,6,6-triethyl-2-oxomorpholin-3-yl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)-2-methylpropanamide;
2-(4-benzyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
N-(4-isopropylphenyl)-2-(4,6,6-trimethyl-2-oxomorpholin-3-yl)acetamide;
2-(6,6-dimethyl-2-oxo-4-propylmorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-cyclopentyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-isopropyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-cyclopropyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(6,6-dimethyl-2-oxo-4-(2,2,2-trifluoroethyl)morpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-(2-fluoroethyl)-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-acetyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(6,6-dimethyl-4-(methylsulfonyl)-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(6,6-dimethyl-2-oxo-4-phenylmorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide;
4-ethyl-6,6-dimethyl-3-(2-morpholino-2-oxoethyl)morpholin-2-one.

### Claim 8 (depends on 1)

The compound according to claim 1 for use as a medicament.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein the medicament is for the prevention or treatment of fungal infection in a subject.

### Claim 10 (depends on 9)

The compound according to claim 9, wherein said fungal infection is caused by Candida species, Aspergillus species or Fusarium species.

### Claim 11 (depends on 10)

The compound according to claim 10, wherein said fungal infection is a systemic infection.

### Claim 12 (depends on 10)

The compound according to claim 10, wherein said fungal infection is a topical infection.

### Claim 13 (depends on 1)

The use of a compound according to claim 1 for the manufacture of a medicament.

### Claim 14 (depends on 13)

The use of a compound according to claim 13 wherein said medicament is for the prevention or treatment of a fungal infection in a subject.

### Claim 15 (depends on 14)

The use according to claim 14 wherein said fungal infection is caused by Candida species, Aspergillus species or Fusarium species.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient in admixture with at least a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

A pharmaceutical composition according to claim 16 having antifungal activity.

### Claim 18 (depends on 1)

A method to treat or to prevent a fungal infection in a subject, comprising administering to the subject in need of such treatment a therapeutically effective amount of a compound according to claim 1.

### Claim 19 (depends on 1)

A method for the preparation of the compound according to claim 1, comprising the steps of:
preparing a substituted morpholin-2-one derivative by condensation of a suitable amino-alcohol derivative with glyoxal or with a suitable acetate derivative of formula LG-CH2—COOR (R being preferably an alkyl or a benzyl radical)
reacting this morpholin-2-one derivative with a suitable acetate derivative of formula LG-CH2—COOR(R being preferably an alkyl or a benzyl radical) in order to obtain a 2-(substituted-2-oxomorpholin-3-yl)acetate derivative;
converting the obtained ester in a carboxylic acid derivative via a saponification reaction
converting the acid derivative in a desired amide derivative using standard peptide coupling reagents.
preparing a 2-(4-benzyl-2-oxomorpholin-3-yl)-N-substituted acetamide derivative using the previous detailed step
removing the N-benzyl protecting group from the morpholin-2-one derivative in order to obtain a 2-(2-oxomorpholin-3-yl)-N-substituted acetamide derivative
condensing the 2-(2-oxomorpholin-3-yl)-N-substituted acetamide derivative with a suitable reagent in order to substitute the free nitrogen atom from the morpholin-2-one ring and obtain the desired compounds.
